Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics starts dosing for injected hay fever vaccine trial

Results are expected in the second half of 2018, following which Allergy will start work on the parameters for the Phase III trial
picture of needle
The hay-fever treatment is injected

Dosing has started in the Phase II study of Allergy Therapeutics plc’s (LON:AGL) injected, aluminium-free, hay fever vaccine. 

Results are expected in the second half of 2018, following which Allergy will expect to start work on the parameters for the Phase III trial.

READ: Allergy Therapeutics - strong financial showing, solid cash position, progress in the clinic

The year-long study, which will involve 440 patients across Germany, Austria and Poland, is designed to identify the optimal effective dose and will adopt the challenge testing method used recently in a birch pollen allergy study.

If approved, the product will be the first registered subcutaneous (injected under the skin) immunotherapy product in the US for allergy.

The US allergy immunotherapy market might be worth as much as US$2bn currently with grass vaccine sales of US$300-400mln per annum.

WATCH: Allergy Therapeutics preparing the ground for big opportunities in the US

Manuel Llobet, Allergy’s chief executive, said: "The start of treatment in this important Phase II trial marks an exciting and critical period of trials for the group's research and development pipeline.

"This trial aims to strengthen the Group's portfolio in Europe and the US and takes us another step closer to treating patients in the major US market."

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
scientist with vial
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use